BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 20942629)

  • 1. EGF receptor in lung cancer: a successful story of targeted therapy.
    Domingo G; Perez CA; Velez M; Cudris J; Raez LE; Santos ES
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1577-87. PubMed ID: 20942629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer.
    Batus M; Fidler MJ; Bonomi PD
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1589-99. PubMed ID: 20942630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personalized medicine for non-small-cell lung cancer.
    Mok TS; Zhou Q; Leung L; Loong HH
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1601-11. PubMed ID: 20942631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted therapies for non-small cell lung cancer.
    Dempke WC; Suto T; Reck M
    Lung Cancer; 2010 Mar; 67(3):257-74. PubMed ID: 19914732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of EGFR inhibition in the treatment of non-small cell lung cancer.
    Ray M; Salgia R; Vokes EE
    Oncologist; 2009 Nov; 14(11):1116-30. PubMed ID: 19892771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor as a target in cancer therapy.
    Kim ES
    J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S87-95. PubMed ID: 19795581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of serum hepatocyte growth factor on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung adenocarcinoma.
    Kasahara K; Arao T; Sakai K; Matsumoto K; Sakai A; Kimura H; Sone T; Horiike A; Nishio M; Ohira T; Ikeda N; Yamanaka T; Saijo N; Nishio K
    Clin Cancer Res; 2010 Sep; 16(18):4616-24. PubMed ID: 20679350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies.
    Stella GM; Luisetti M; Inghilleri S; Cemmi F; Scabini R; Zorzetto M; Pozzi E
    Respir Med; 2012 Feb; 106(2):173-83. PubMed ID: 22104541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR-directed therapies to treat non-small-cell lung cancer.
    Ho C; Laskin J
    Expert Opin Investig Drugs; 2009 Aug; 18(8):1133-45. PubMed ID: 19572809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer.
    Heymach JV; Nilsson M; Blumenschein G; Papadimitrakopoulou V; Herbst R
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4441s-4445s. PubMed ID: 16857825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
    John T; Liu G; Tsao MS
    Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC.
    Maione P; Gridelli C; Troiani T; Ciardiello F
    Oncologist; 2006 Mar; 11(3):274-84. PubMed ID: 16549812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.
    Crawford J
    J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S78-86. PubMed ID: 19795580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line treatment for advanced nonsmall cell lung cancer harboring activating epidermal growth factor receptor mutation: epidermal growth factor receptor tyrosine kinase inhibitors or chemotherapy?
    Gridelli C
    Curr Opin Oncol; 2011 Mar; 23(2):131-2. PubMed ID: 21307676
    [No Abstract]   [Full Text] [Related]  

  • 15. Progress in cancer chemotherapy with special stress on molecular-targeted therapy.
    Saijo N
    Jpn J Clin Oncol; 2010 Sep; 40(9):855-62. PubMed ID: 20651047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Target population and predictive factors of survival and efficacy of anti-HER1/EGFR drugs].
    Cadranel J
    Rev Pneumol Clin; 2007 Jan; 63(1 Pt 2):2S10-1. PubMed ID: 17242637
    [No Abstract]   [Full Text] [Related]  

  • 17. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
    Pennell NA; Lynch TJ
    Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted therapies in combination with chemotherapy in non-small cell lung cancer.
    Johnson DH
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4451s-4457s. PubMed ID: 16857827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor receptor pathway targeted therapy in patients with aerodigestive malignancies.
    Patel JD
    Curr Opin Oncol; 2006 Nov; 18(6):609-14. PubMed ID: 16988582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New targets for non-small-cell lung cancer therapy.
    Alvarez M; Roman E; Santos ES; Raez LE
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1423-37. PubMed ID: 17944567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.